fbpx

molecules of the month

baxdrostat

oral aldosterone synthase (CYP11B2) inhibitor

Ph. I/II for HTN, CKD, primary aldosteronism

from in-house screen of aldosterone synthase inhibitors

Press release, January 9, 2023

Roche, Basel, CH (AstraZeneca)

baxdrostat chemical structure oral aldosterone synthase (CYP11B2) inhibitor - Roche, Basel, CH (AstraZeneca)
6 mins read

What is it? Baxdrostat (RO6836191, CIN-107) is an oral aldosterone synthase (CYP11B2) inhibitor in several Ph. II trials (0.5-2 mg QD) for hypertension, CKD, and primary aldosteronism. The molecule is highly selective (>100x) against a cortisol synthesis enzyme, CYP11B1, allowing it to avoid negative effects due to cortisol reduction in the clinic, a longstanding challenge for clinical application of aldosterone synthase inhibitors. The molecule demonstrated dose-dependent PK/PD and overwhelming, trial-stopping efficacy in terms of reductions in systolic and diastolic blood pressure in hypertensive patients, contributing to the value of its recent $1.8B acquisition by AstraZeneca via CinCor. Originally discovered by Roche, it was out-licensed to a Cincinnati company with a 2022 IPO, CinCor, after Roche exited CV drug development, and…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: